Marianne Oulhen

Villejuif, 94805, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Isolation and Sequencing of Single Circulating Tumor Cells.

Isolation and Sequencing of Single Circulating Tumor Cells.

Journal: Methods in molecular biology (Clifton, N.J.)
Published: July 09, 2026

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.

Journal: Cancer cell
Published: July 07, 2025

Patritumab deruxtecan in HR+HER2- advanced breast cancer: a phase 2 trial.

Patritumab deruxtecan in HR+HER2- advanced breast cancer: a phase 2 trial.

Journal: Nature medicine
Published: March 31, 2025

Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.

Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.

Journal: British journal of cancer
Published: July 02, 2023

Targeting genome integrity dysfunctions impedes metastatic potency in non-small cell lung cancer circulating tumor cell-derived explants.

Targeting genome integrity dysfunctions impedes metastatic potency in non-small cell lung cancer circulating tumor cell-derived explants.

Journal: JCI insight
Published: October 21, 2021

Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability.

Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability.

Journal: Cells
Published: January 13, 2021

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.

Journal: NPJ precision oncology
Published: December 16, 2020

Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID.

Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID.

Journal: Clinical chemistry
Published: May 28, 2020

Exploitation of the chick embryo chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing.

Exploitation of the chick embryo chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing.

Journal: Scientific reports
Published: January 29, 2020

CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs).

CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs).

Journal: Cells
Published: July 11, 2019

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer.

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 09, 2019

Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies.

Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies.

Journal: Journal of thoracic disease
Published: February 19, 2019
Showing 1-12 of 24

Last Updated: 09/26/2026